NCT04477642View on ClinicalTrials.gov

Abatacept for Patients With COVID-19 and Respiratory Distress

PHASE1/PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2020

Primary Completion Date

October 31, 2020

Study Completion Date

December 31, 2020

Conditions

COVID-19

Interventions

DRUG

Abatacept

10mg/kg intravenously administered on Day 1

Trial Locations (2)

02215

Beth Israel Deaconess Medical Center, Boston

Boston Children's Hospital, Boston

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Boston Children's Hospital

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Brigham and Women's Hospital

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT04477642 - Abatacept for Patients With COVID-19 and Respiratory Distress | Biotech Hunter | Biotech Hunter